You are here: Industry Insights > Jacobio

News List

Jacobio Receives IND Approval for Aurora A Inhibitor JAB-2485 from FDA prnasia
January 17, 2022
Jacobio's self-developed global first-in-class drug Aurora A inhibitor JAB-2485 received IND (Investigational New Drug) from the FDA (Food and Drug Administration) in US. Jacobio plans to initiate...
Jacobio Receives IND Approval for Combination Therapy of KRAS G12C and Cetuximab Injection in China prnasia
December 06, 2021
Jacobio Pharma (1167.HK) has received the Investigational New Drug (the "IND") approval of the combination therapy of KRAS G12C inhibitor JAB-21822 and Cetuximab injection from the Center for Drug Evaluation of China (the "CDE") on Dec 3, 2021.
Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumor prnasia
August 03, 2021
Jacobio Pharmaceuticals today announced the first patient was dosed in a Phase I/II clinical trial of KRAS G12C inhibitor JAB-21822 in China.
Jacobio Earns $20M AbbVie Milestone contractpharma
June 21, 2021
Jacobio Pharmaceuticals dosed the first two patients in the Phase 1/2a clinical trial of SHP2 inhibitor JAB-3312 in combination with PD-1 antibody Pembrolizumab and MEK inhibitor Binimetinib respectively, triggering a $20 million milestone payment ...
Jacobio Announces First Two Patients Dosed in SHP2 Combination Study, Triggering US$20 Million Milestone Payment prnasia
June 18, 2021
Jacobio Pharmaceuticals has announced that the first two patients have been dosed in the Phase 1/2a clinical trial of SHP2 inhibitor JAB-3312 in combination with PD-1 antibody Pembrolizumab and MEK inhibitor Binimetinib respectively ...
Jacobio Pharma Announces CNY486 Million Revenue for 2020 Annual Results prnasia
March 29, 2021
Jacobio Pharmaceuticals announced its first annual results after its Hong Kong, S.A.R., China listing. By the end of December 31, 2020, its annual revenue was 486 million yuan and R&D expenses exceeded 230 million yuan and increased 66% compared to 2019.